Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: A systematic review

Liver Transplantation

Volumn 17, Issue 10, 2011, Pages 1176-1190

  Cholongitas, Evangelos ^a   Goulis, John ^a   Akriviadis, Evangelos ^a   Papatheodoridis, Geore V ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B ANTIBODY; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE;

CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GRAFT RECIPIENT; HEPATITIS B; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MEDLINE; META ANALYSIS; MONOTHERAPY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REVIEW; SYSTEMATIC REVIEW;

ADENINE; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; PHOSPHONIC ACIDS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052635201     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22354     Document Type: Review

References (67)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
2. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK,. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29: 1294-1305.
3. Degertekin B, Lok AS,. Indications for therapy in hepatitis B. Hepatology 2009; 49 (suppl): S129-S137.
4. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A,. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-356.
5. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H,. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847. (Pubitemid 23360483)
6. Papatheodoridis GV, Sevastianos V, Burroughs AK,. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 2003; 3: 250-258. (Pubitemid 36407041)
7. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, Csako G,. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 696-700.
8. Katz LH, Paul M, Guy DG, Tur-Kaspa R,. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis 2010; 12: 292-308.
9. Samuel D,. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004; 24 (suppl 1): 55-62. (Pubitemid 38738359)
10. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589. (Pubitemid 28363690)
11. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R, Gish RR,. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491-496. (Pubitemid 29517864)
12. Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520-525. (Pubitemid 29517869)
13. McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 512-519. (Pubitemid 29517868)
14. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H,. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-433. (Pubitemid 30489114)
15. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-910. (Pubitemid 32595191)
16. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Böker KHW,. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902. (Pubitemid 32595190)
17. Honaker MR, Shokouh-Amiri MH, Vera SR, Alloway RR, Grewal HP, Hardinger KL, et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl Infect Dis 2002; 4: 137-143. (Pubitemid 35364777)
18. Steinmüller T, Seehofer D, Rayes N, Müller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-1535. (Pubitemid 34966909)
19. Park SJ, Paik SW, Choi MS, Lee JH, Koh KC, Kim SJ, et al. Is lamivudine with 1-week HBIg as effective as long-term high-dose HBIg in HBV prophylaxis after liver transplantation? Transplant Proc 2002; 34: 1252-1254. (Pubitemid 34665332)
20. Sousa JM, Pareja F, Serrano J, Gõmez MA, García I, Tamayo MJ, et al. Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation. Transplant Proc 2003; 35: 723-724. (Pubitemid 36338133)
21. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O,. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 2003; 3: 999-1002. (Pubitemid 36917547)
22. Ben-Ari Z, Mor E, Bar-Nathan N, Shaharabani E, Shapira Z, Tur-Kaspa R,. Combination hepatitis B immune globulin and lamivudine versus hepatitis B immune globulin monotherapy in preventing recurrent hepatitis B virus infection in liver transplant recipients. Transplant Proc 2003; 35: 609-611. (Pubitemid 36338087)
23. Zhu JP, Zhang TL, Li L, Yuan J, Song SB, Xiu DR, et al. Prevention and treatment of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2003; 2: 500-503. (Pubitemid 37441665)
24. Ferretti G, Merli M, Ginanni Corradini S, Callejon V, Tanzilli P, Masini A, et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 2004; 36: 535-538. (Pubitemid 38534313)
25. Wang ZX, Fu ZR, Ding GS, Zhang JJ, Fu H, Zhang M, Zhang CY,. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Transplant Proc 2004; 36: 2315-2317. (Pubitemid 39550830)
26. Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST,. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807-813. (Pubitemid 40975583)
27. Marzano A, Lampertico P, Mazzaferro V, Carenzi S, Vigano M, Romito R, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 532-538. (Pubitemid 40704065)
28. Caccamo L, Romeo R, Rossi G, Maggioni M, Radice F, Lunghi G, et al. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants. Transpl Int 2005; 18: 186-192. (Pubitemid 41743309)
29. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M,. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-258. (Pubitemid 43273784)
30. Karademir S, AstarcioÄlu H, Akarsu M, Ozkardesler S, Ozzeybek D, Sayiner A, et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant Proc 2006; 38: 579-583.
31. Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A,. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006; 20: 206-210.
32. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al.; for Adefovir Dipivoxil Study, 45 International Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-360. (Pubitemid 46444463)
33. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, McCaughan GW,; for Australasian Liver Transplant Study Group. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937. (Pubitemid 46440868)
34. Anderson RD, Chinnakotla S, Guo L, Perrillo RP, Klintmalm GB, Davis GL,. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. Clin Transplant 2007; 21: 510-517. (Pubitemid 47161828)
35. Yi NJ, Suh KS, Cho JY, Kwon CH, Lee KW, Joh JW, et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007; 13: 451-458. (Pubitemid 46444475)
36. Yoshida H, Kato T, Levi DM, Regev A, Madariaga JR, Nishida S, et al. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin Transplant 2007; 21: 166-171. (Pubitemid 46505722)
37. Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, Lok AS,. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13: 374-381. (Pubitemid 46444466)
38. Neff GW, Kemmer N, Kaiser TE, Zacharias VC, Alonzo M, Thomas M, Buell J,. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007; 52: 2497-2500. (Pubitemid 47373893)
39. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Busuttil RW,. Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Transplant Proc 2007; 39: 3276-3280. (Pubitemid 350258646)
40. Akyildiz M, Karasu Z, Zeytunlu M, Aydin U, Ozacar T, Kilic M,. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 2007; 22: 2130-2134. (Pubitemid 350145596)
41. Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007; 84: 650-654. (Pubitemid 47429048)
42. Takaki A, Yagi T, Iwasaki Y, Sadamori H, Matsukawa H, Matsuda H, et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 2007; 83: 231-233. (Pubitemid 46185216)
43. Yang Y, Zhang Q, Cai CJ, Lu MQ, Li X, Jiang N, et al. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant. Chin Med J (Engl) 2007; 120: 1400-1403. (Pubitemid 47364969)
44. Freshwater DA, Dudley T, Cane P, Mutimer DJ,. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 2008; 85: 1105-1111. (Pubitemid 351590187)
45. Hooman N, Rifai K, Hadem J, Vaske B, Philipp G, Priess A, et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008; 14: 435-442. (Pubitemid 351524398)
46. Yilmaz N, Shiffman ML, Todd Stravitz R, Sterling RK, Luketic VA, Sanyal AJ, et al. Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int 2008; 28: 72-78.
47. Lu AW, Zheng SS, Wu MP, Shen Y, Yang RW,. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2008; 7: 357-361.
48. Avolio AW, Nure E, Pompili M, Barbarino R, Basso M, Caccamo L, et al. Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. Transplant Proc 2008; 40: 1961-1964.
49. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E,. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-1466.
50. Ahn S, Dodson SF, Cohen SM,. Oral antiviral therapy without long term maintenance hepatitis B immunoglobulin to prevent hepatitis B recurrence in liver transplant patients [abstract]. J Hepatol 2008; 48 (suppl 2): S73-S74.
51. Giusto M, Gentilli F, Loria I, Grieco S, Rossi M, Novelli G, et al. Combined therapy with low dose hepatitis B immunoglobulin (HBIG) and lamivudine (LAM) in patients transplanted for HBV chronic liver disease: long term efficacy and costs [abstract]. J Hepatol 2008; 48 (suppl 2): S84.
52. Woo HY, Choi JY, Jang JW, You CR, Bae SH, Yoon SK, et al. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J Med Virol 2008; 80: 1891-1899.
53. Beckebaum S, Sotiropoulos GC, Klein CG, Broelsch CE, Saner F, Paul A, et al. Predictive factors of outcome in patients transplanted for hepatitis B. Transplantation 2009; 87: 872-881.
54. Jiang L, Yan L, Li B, Wen T, Zhao J, Jiang L, et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant 2010; 10: 1861-1869.
55. Degertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, Brown RS Jr, et al.; for NIH HBV-OLT Study Group. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010; 10: 1823-1833.
56. Karasu Z, Ozacar T, Akyildiz M, Demirbas T, Arikan C, Kobat A, et al. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther 2004; 9: 921-927. (Pubitemid 40040266)
57. Seehofer D, Rayes N, Steinmüller T, Müller AR, Settmacher U, Neuhaus R, et al. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transpl 2001; 7: 976-982. (Pubitemid 33085787)
58. Chu CJ, Fontana RJ, Moore C, Armstrong DR, Punch JD, Su GL, et al. Outcome of liver transplantation for hepatitis B: report of a single center's experience. Liver Transpl 2001; 7: 724-731. (Pubitemid 32771473)
59. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002; 235: 611-619.
60. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-748.
61. Neff GW, O'Brien CB, Nery J, Shire N, Montalbano M, Ruiz P, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004; 10: 1372-1378. (Pubitemid 39530052)
62. Lee PH, Hu RH, Tsai MK, Ho MC, Lai HS, Lai MY, Yang PM,. Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous antihepatitis B immunoglobulin and lamivudine. Transplant Proc 2000; 32: 2245-2247.
63. Jiao ZY, Jiao Z,. Prophylaxis of recurrent hepatitis B in Chinese patients after liver transplantation using lamivudine combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen. Transplant Proc 2007; 39: 1533-1536. (Pubitemid 46907920)
64. Chun J, Kim W, Kim BG, Lee KL, Suh KS, Yi NJ, et al. High viremia, prolonged lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant 2010; 10: 1649-1659.
65. Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Wang X, et al. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis 2009; 10: 321-327.
66. Rao W, Wu X, Xiu D,. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int 2009; 22: 387-394.
67. Ghany MG, Doo EC,. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49 (suppl): S174-S184.